Cortisol_NN
receptor_NN
resistance_NN
:_:
the_DT
variability_NN
of_IN
its_PRP$
clinical_JJ
presentation_NN
and_CC
response_NN
to_TO
treatment_NN
._.

Primary_JJ
-LRB-_-LRB-
partial_JJ
-RRB-_-RRB-
cortisol_NN
receptor_NN
resistance_NN
was_VBD
previously_RB
reported_VBN
in_IN
a_DT
total_NN
of_IN
7_CD
patients_NNS
and_CC
14_CD
asymptomatic_JJ
family_NN
members_NNS
._.

Its_PRP$
occurrence_NN
is_VBZ
considered_VBN
to_TO
be_VB
extremely_RB
rare_JJ
._.

In_IN
the_DT
present_JJ
study_NN
we_PRP
report_VBP
on_IN
6_CD
patients_NNS
-LRB-_-LRB-
2_CD
males_NNS
and_CC
4_CD
females_NNS
-RRB-_-RRB-
with_IN
the_DT
syndrome_NN
._.

The_DT
first_JJ
male_JJ
patient_NN
presented_VBD
with_IN
mild_JJ
hypertension_NN
._.

Hydrochlorothiazide_NN
therapy_NN
resulted_VBD
in_IN
life-threatening_JJ
hypokalemia_NN
._.

The_DT
second_JJ
male_JJ
patient_NN
had_VBD
slight_JJ
hypertension_NN
without_IN
hypokalemia_NN
._.

All_DT
four_CD
female_JJ
patients_NNS
presented_VBD
between_IN
the_DT
age_NN
of_IN
20-30_CD
yr_NN
with_IN
acne_NN
,_,
hirsutism_NN
,_,
and_CC
irregular_JJ
menstruations_NNS
._.

Low_JJ
dose_NN
dexamethasone_NN
therapy_NN
-LRB-_-LRB-
1-1_CD
.5_CD
mg\/day_NN
-RRB-_-RRB-
was_VBD
of_IN
clinical_JJ
benefit_NN
in_IN
these_DT
patients_NNS
._.

All_DT
patients_NNS
showed_VBD
insufficient_JJ
suppression_NN
of_IN
serum_NN
cortisol_NN
concentrations_NNS
in_IN
the_DT
overnight_JJ
1-mg_JJ
dexamethasone_NN
test_NN
._.

The_DT
diurnal_JJ
rhythm_NN
of_IN
ACTH_NN
and_CC
cortisol_NN
was_VBD
intact_JJ
,_,
albeit_IN
at_IN
an_DT
elevated_JJ
level_NN
._.

There_EX
was_VBD
a_DT
normal_JJ
increase_NN
in_IN
ACTH_NN
,_,
cortisol_NN
,_,
and_CC
GH_NN
-LRB-_-LRB-
except_IN
in_IN
one_CD
obese_JJ
patient_NN
-RRB-_-RRB-
in_IN
response_NN
to_TO
insulin-induced_JJ
hypoglycemia_NN
,_,
while_IN
cortisol_NN
production_NN
was_VBD
elevated_VBN
in_IN
three_CD
patients_NNS
._.

Circulating_VBG
adrenal_JJ
androgen_NN
levels_NNS
were_VBD
increased_VBN
in_IN
all_DT
patients_NNS
._.

Glucocorticoid_NN
receptors_NNS
were_VBD
investigated_VBN
in_IN
a_DT
whole_JJ
cell_NN
dexamethasone_NN
binding_NN
assay_NN
in_IN
mononuclear_JJ
leukocytes_NNS
._.

In_IN
the_DT
first_JJ
male_JJ
patient_NN
,_,
the_DT
number_NN
of_IN
receptors_NNS
was_VBD
very_RB
low_JJ
,_,
while_IN
the_DT
affinity_NN
was_VBD
lower_JJR
than_IN
that_DT
in_IN
controls_NNS
._.

A_DT
lowered_JJ
affinity_NN
to_TO
dexamethasone_NN
was_VBD
found_VBN
in_IN
one_CD
female_JJ
patient_NN
,_,
while_IN
a_DT
lowered_JJ
number_NN
of_IN
receptors_NNS
was_VBD
found_VBN
in_IN
three_CD
patients_NNS
._.

In_IN
the_DT
second_JJ
male_JJ
patient_NN
,_,
no_DT
abnormalities_NNS
were_VBD
found_VBN
._.

As_IN
a_DT
bioassay_NN
for_IN
glucocorticoid_NN
action_NN
we_PRP
also_RB
measured_VBD
dexamethasone_NN
suppressibility_NN
of_IN
mitogen-stimulated_JJ
incorporation_NN
of_IN
-LCB-_-LRB-
3H-RCB-thymidine_NN
in_IN
mononuclear_JJ
leukocytes_NNS
._.

In_IN
the_DT
male_JJ
patient_NN
with_IN
normal_JJ
receptor_NN
status_NN
,_,
dexamethasone_NN
suppressibility_NN
of_IN
-LCB-_-LRB-
3H-RCB-thymidine_NN
incorporation_NN
was_VBD
significantly_RB
lower_JJR
than_IN
that_DT
in_IN
healthy_JJ
controls_NNS
with_IN
respect_NN
to_TO
both_CC
maximal_JJ
suppression_NN
and_CC
IC50_NN
._.

Partial_JJ
cortisol_NN
receptor_NN
resistance_NN
might_MD
be_VB
less_RBR
rare_JJ
than_IN
previously_RB
thought_VBN
._.

In_IN
the_DT
six_CD
patients_NNS
presented_VBN
,_,
at_IN
least_JJS
three_CD
different_JJ
forms_NNS
can_MD
be_VB
recognized_VBN
._.

Therapy_NN
with_IN
dexamethasone_NN
was_VBD
successful_JJ
in_IN
female_JJ
patients_NNS
with_IN
acne_NN
and_CC
hirsutism_NN
,_,
as_IN
the_DT
secondary_JJ
increase_NN
in_IN
the_DT
production_NN
of_IN
adrenal_JJ
androgens_NNS
was_VBD
effectively_RB
controlled_VBN
._.

